General MM

ASCO 2019 | Overview of the PROMMIS study

L:

Binod Dhakal, Medical College of Wisconsin, Milwaukee, US, presents the PROMMIS study which prospectively measured the impact of MMprofiler on treatment intention in newly diagnosed multiple myeloma (NDMM). This interview was conducted during ASCO 2019, held in Chicago, US. Binod Dhakal discusses how MMprofiler (92 gene) was utilized to classify patients within risk categories and then assist in determining treatment. For NDMM, the MMprofiler was helpful to confirm treatment and the trial is continuing to enroll, with further data expected at EHA 2019.